Compare Biogen Inc (BIIB) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Consolidated Edison, Inc. — how do they compare? Biogen Inc trades at $191.89 (market cap $28.34B), while Consolidated Edison, Inc. trades at $111.89 (market cap $41.26B). The key difference: Consolidated Edison, Inc. is the larger of the two by market cap, and Consolidated Edison, Inc. pays a 3.1% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | ED | |
|---|---|---|
Market Cap | $28.34B | $41.26B |
Sector | Health | Utilities |
52-Week High | $216.63 | $115.46 |
52-Week Low | $122.68 | $95.37 |
Enterprise Value | $30.62B | $68.29B |
Dividend Yield | — | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Consolidated Edison (ED) trades at $111.82, up 0.63% today, with a bullish technical signal from moving averages. The company reported mixed Q1 2026 earnings but maintains stable profitability with a 12.52% net margin. Recent news highlights grid upgrades to meet rising data center demand and the launch of New York's largest electric school bus fleet, supporting long-term growth initiatives.
ED offers a defensive utility profile with a 3.3% dividend yield and 52-year dividend growth streak. However, analyst consensus is cautious with 67% hold ratings and a $103.50 price target below current levels. Key risks include capital expenditure pressures from grid modernization and interest rate sensitivity due to high debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
